Guy Myint Maung

Guy Myint-Maung is a Partner at Amundi Alpha Associates in Zurich and a member of the firm's Private Equity investment team and Investment Committee. The firm says he has been active in private market investing since 2000 and is responsible for due diligence, negotiation, execution and management of fund and direct investments.

He joined Alpha Associates in 2004. Before the team's spin-out from Swiss Life Private Equity Partners, he was an investment manager at SLPEP from 2000. Earlier in his career, he worked at Centre Solutions Zurich, an alternative risk transfer specialist and subsidiary of Zurich Financial Services.

Before Centre Solutions, Myint-Maung spent four years at UBS in Switzerland, mainly in business analysis and controlling functions, first at the European operations level and later globally for the corporate banking and corporate finance divisions. He holds a B.Sc. in Biological Sciences from the University of Sussex, an MBA from Manchester Business School, and is a CFA charterholder.

Amundi announced in February 2024 that it had signed a binding agreement to acquire Alpha Associates. The Alpha platform became part of Amundi's private markets multi-manager business, combining Zurich-based Alpha Associates with Amundi's existing private markets multi-manager activities.

• Focuses on private equity buyout and venture investments, including life sciences and medical technology.
• Handles both fund and direct investments, with a geographic focus on the U.S. and Emerging Markets.
• Amundi Alpha Associates' stated strategy is to use its global primary fund-investing platform to access secondary and direct co-investment opportunities.
• For primary fund investments, the firm says it looks for "established teams with proven track records, strong alignment of interest, and robust governance frameworks."
• For venture, Amundi Alpha Associates says it concentrates on late-stage venture strategies where business models are more developed and risk is mitigated by operating and revenue visibility, especially in technology and life sciences.
• For direct co-investments, the firm says it invests alongside fund managers in specific companies and selects opportunities with a superior risk-return profile through rigorous due diligence.